Kalaris Therapeutics management to join Morgan Stanley Global Healthcare Conference fireside chatPUBT·Aug 31 at 12:03 PMKLRS+1.03%MS+2.52%
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings ResultsMarket Beat·Aug 11 at 01:11 PMKLRS+1.03%
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on HandTradingView·Aug 11 at 12:13 PMKLRS+1.03%
Kalaris announces Q2 2026 financials, along with business updates.Unusual Whales·Aug 11 at 12:02 PMKLRS+1.03%
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What HappenedMarket Beat·Aug 4 at 06:20 AMKLRS+1.03%
Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statementPUBT·Aug 3 at 08:02 PMKLRS+1.03%
Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statementPUBT·Jul 27 at 08:05 PMKLRS+1.03%
Kalaris names Liisa Bayko CFO and Amy Vandekop interim principal accounting officerTradingView·Jul 20 at 12:13 PMKLRS+1.03%
